Research-only: Recovery + Skin (GLOW-style grouping)

Public • 2/6/2026

Adds a copper peptide often discussed in cosmetic/skin contexts to a recovery/joint pairing. Evidence is indirect and component-based.

← Back Buy stack

Practical pre-check

Deterministic heuristics (stimulants, duplicates, hydration). Not medical advice.

Supplements

Items in this stack

Training load

Unknown load

Need more wearable data

Stimulant estimate

0 mg

Only counts explicit caffeine items

Looks clean

No obvious duplication/stimulant/hydration flags from the heuristic pass.

AI risk assessment

Context: No wearable data

No assessment yet.

Supplements

3 items

BPC-157Low

PLACEHOLDER • Lyophilized • Click to expand

Preclinical repair signals; limited human evidence.

Buy ingredient →

1mg

Safety / pharmacokinetics

Low

Population: Healthy volunteers

Study type: Registered phase 1 trial (results not posted)

Dose context: — • Duration: See registry

A phase 1 safety/PK study in healthy volunteers was registered; results were not posted and the submission was canceled per later reviews, limiting interpretability.

Citation: ClinicalTrials.gov NCT02637284 — PCO-02 Safety and Pharmacokinetics Trial•https://clinicaltrials.gov/study/NCT02637284

Soft tissue healing signals (preclinical)

Low

Population: Animal models (multiple tissues)

Study type: Review (preclinical-focused)

Dose context: —

Multiple preclinical models report improvements in healing-related endpoints; translation to humans remains unproven.

Citation: Cushman et al., Local and Systemic Peptide Therapies for Soft Tissue Healing (2024)•https://pmc.ncbi.nlm.nih.gov/articles/PMC11426299/

Musculoskeletal healing (preclinical)

Low

Population: Animal injury models (multiple tissues)

Study type: Narrative review of preclinical evidence

Dose context: —

Across animal models, BPC-157 is frequently reported to improve healing-related outcomes (tendon/ligament/muscle/bone and GI injury models), but translation to humans remains unproven.

Citation: Vasireddi et al., (2025) — Emerging Use of BPC-157 in Orthopaedic Sports Medicine (review)•https://pmc.ncbi.nlm.nih.gov/articles/PMC12313605/

TB500 (TB4 / Thymosin Beta-4)Low

PLACEHOLDER • Lyophilized • Click to expand

Preclinical wound-healing biology; athlete outcomes uncertain.

Buy ingredient →

1mg

Wound healing (clinical development)

Low

Population: Patients with venous stasis ulcers

Study type: Registered phase 2 trial (TB4 gel)

Dose context: — • Duration: Up to 84 days (per registry)

TB4 gel has been studied in venous stasis ulcer indications; registry evidence supports clinical testing, though effect sizes depend on the specific trial and endpoint reporting.

Citation: ClinicalTrials.gov NCT00832091 — Thymosin Beta 4 in Venous Stasis Ulcers•https://clinicaltrials.gov/study/NCT00832091

Wound healing

Low

Population: Rat full-thickness wound model

Study type: Preclinical animal study

Dose context: —

TB4 accelerated wound healing endpoints in a rat model compared with controls.

Citation: Malinda et al., J Invest Dermatol (1999)•DOI: 10.1046/j.1523-1747.1999.00708.x•https://pubmed.ncbi.nlm.nih.gov/10469335/

Wound healing (reviewed clinical context)

Low

Population: Stasis and pressure ulcer clinical programs

Study type: Review article

Dose context: —

A review summarizes phase 2 wound-healing programs reporting faster healing in those that did heal; note that these are not sports injury RCTs.

Citation: Treadwell et al., Ann N Y Acad Sci (2012) — The regenerative peptide thymosin β4 accelerates the rate of dermal healing•https://pubmed.ncbi.nlm.nih.gov/23050815/

GHK-CuModerate

PLACEHOLDER • Other • Click to expand

Mixed cosmetic/derm evidence; formulation-dependent.

Buy ingredient →

1mg

Skin appearance / remodeling (summary of clinical + mechanistic evidence)

Moderate

Population: Humans (cosmetic/dermatologic contexts) + preclinical

Study type: Review

Dose context: —

Review summarizes reported improvements in some skin measures and broad tissue-remodeling biology; quality and comparators vary widely. The authors note a surprising absence of rigorous modern clinical trials for GHK-Cu in anti-wrinkle applications despite widespread cosmetic use.

Citation: Pickart et al., Molecules (2018) — Regenerative and Protective Actions of the GHK-Cu Peptide•DOI: 10.3390/molecules23081985•https://pmc.ncbi.nlm.nih.gov/articles/PMC6073405/

Wrinkle improvement (objective measures)

Low

Population: Adults using topical copper tripeptide complex

Study type: Clinical study (objective evaluation)

Dose context: —

One objective evaluation reported no significant improvement in wrinkles/overall skin quality, though patient satisfaction differed; underscores mixed results across formulations and endpoints.

Citation: Miller et al., Arch Facial Plast Surg (2006) — Topical copper tripeptide complex evaluation•DOI: 10.1001/archfaci.8.4.252•https://www.liebertpub.com/abs/doi/10.1001/archfaci.8.4.252